This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Minerva Neurosciences (NERV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Top Ranked Momentum Stocks to Buy for May 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 26th
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for May 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 11th
New Strong Buy Stocks for May 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Company News For Oct 2, 2019
by Zacks Equity Research
Companies In The News Are: ROAN, CFMS, NERV, REED
Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva
by Zacks Equity Research
Zacks.com featured highlights include: ACM Research, GAIN Capital, Cutera, Columbus McKinnon and Minerva
Moving Average Crossover Alert: Minerva Neurosciences
by Zacks Equity Research
Minerva Neurosciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
5 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
J&J Submits NDA to the FDA for Depression Drug in Adults
by Zacks Equity Research
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
by Zacks Equity Research
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
Minerva On Track to Initiate Phase III Schizophrenia Study
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.
Minerva Presents Additional Data from Schizophrenia Drug
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced the results of additional data analyses from phase IIb clinical trial of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.